Medical Adjuvant Therapy in Reducing Thrombosis With Arteriovenous Grafts  and Fistulae Use: A Meta-Analysis of Randomized Controlled Trials

Ullah, Kaleem; Bashir, Maham; Ain, Noor Ul; Sarfraz, Azza; Sarfraz, Zouina; Sarfraz, Muzna; Chérrez-Ojeda, Iván

doi:10.1177/10760296211063882

Cited by 4 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of medications started perioperatively to prevent or improve flow-related arteriovenous access dysfunction remains unresolved despite a meta-analysis of 13 RCTs (1985 patients) . Older data of small short-term (<1 month) studies suggested ticlopidine may provide limited (<1 month) patency benefit for AVFs (10.5%-25.0% thrombosis in ticlopidine vs 47.1%-50.0% placebo); however, subsequent larger long-term RCTs have not been conducted to support this supposed advantage. For AVGs, aspirin-dipyridamole or fish oil may provide primary patency benefit and reduce the need for interventions to maintain patency for AVGs .…”

Section: Arteriovenous Access Complicationsmentioning

confidence: 99%

Arteriovenous Access for Hemodialysis

Lok,

Huber,

Orchanian-Cheff

et al. 2024

JAMA

View full text Add to dashboard Cite

ImportanceHemodialysis requires reliable vascular access to the patient’s blood circulation, such as an arteriovenous access in the form of an autogenous arteriovenous fistula or nonautogenous arteriovenous graft. This Review addresses key issues associated with the construction and maintenance of hemodialysis arteriovenous access.ObservationsAll patients with kidney failure should have an individualized strategy (known as Patient Life-Plan, Access Needs, or PLAN) for kidney replacement therapy and dialysis access, including contingency plans for access failure. Patients should be referred for hemodialysis access when their estimated glomerular filtration rate progressively decreases to 15 to 20 mL/min, or when their peritoneal dialysis, kidney transplant, or current vascular access is failing. Patients with chronic kidney disease should limit or avoid vascular procedures that may complicate future arteriovenous access, such as antecubital venipuncture or peripheral insertion of central catheters. Autogenous arteriovenous fistulas require 3 to 6 months to mature, whereas standard arteriovenous grafts can be used 2 to 4 weeks after being established, and “early-cannulation” grafts can be used within 24 to 72 hours of creation. The prime pathologic lesion of flow-related complications of arteriovenous access is intimal hyperplasia within the arteriovenous access that can lead to stenosis, maturation failure (33%-62% at 6 months), or poor patency (60%-63% at 2 years) and suboptimal dialysis. Nonflow complications such as access-related hand ischemia (“steal syndrome”; 1%-8% of patients) and arteriovenous access infection require timely identification and treatment. An arteriovenous access at high risk of hemorrhaging is a surgical emergency.Conclusions and RelevanceThe selection, creation, and maintenance of arteriovenous access for hemodialysis vascular access is critical for patients with kidney failure. Generalist clinicians play an important role in protecting current and future arteriovenous access; identifying arteriovenous access complications such as infection, steal syndrome, and high-output cardiac failure; and making timely referrals to facilitate arteriovenous access creation and treatment of arteriovenous access complications.

show abstract

Section: Arteriovenous Access Complicationsmentioning

confidence: 99%